Avantor names Mary Blenn as new EVP and chief operating officer

RADNOR, Pa. - Avantor, Inc. (NYSE:AVTR) has appointed Mary Blenn to the newly created position of Executive Vice President and Chief Operating Officer, effective immediately, the company announced Monday. The appointment comes as the $7.87 billion market cap company faces challenges, with its stock trading near its 52-week low of $10.82.

Blenn will report directly to President and CEO Emmanuel Ligner and will oversee Avantor’s manufacturing and supply chain operations. Her responsibilities include aligning the company’s manufacturing and logistics network with its growth strategy and improving efficiency. This leadership change comes as Avantor manages $6.58 billion in revenue with negative growth of 3.59% over the last twelve months, according to InvestingPro data.

With more than 30 years of experience in global operations, manufacturing, and supply chain leadership, Blenn most recently served as Senior Vice President of Global Operations & Supply Chain at Cytiva. She previously held senior leadership roles at General Electric across its healthcare and biopharma divisions.

"Having worked with Mary before, I’ve seen firsthand her ability to transform complex operations into agile, high-performing systems," said Ligner in the press release. He noted her experience in leading manufacturing and supply chain organizations through periods of growth makes her well-suited for the position.

Blenn stated she looks forward to strengthening Avantor’s manufacturing and supply chain capabilities and embedding lean principles throughout the organization. Her appointment could be pivotal as InvestingPro analysis shows Avantor is currently undervalued and analysts predict the company will return to profitability this year with a forecasted EPS of $0.90, despite not being profitable over the last twelve months.

Avantor provides products and services to customers in the life sciences and advanced technologies industries, serving more than 300,000 customer locations across 180 countries, according to the company statement. The company currently generates $1.08 billion in EBITDA and is one of 1,400+ US equities covered by comprehensive Pro Research Reports available through InvestingPro.

In other recent news, Avantor Inc. reported its third-quarter earnings for 2025, revealing a slight miss in both earnings per share (EPS) and revenue compared to forecasts. The company reported an EPS of $0.22, just below the anticipated $0.23, and generated $1.62 billion in revenue, missing the forecast of $1.65 billion. Following these results, Raymond James downgraded Avantor’s stock from Outperform to Market Perform, citing the company’s disappointing quarter. Similarly, JPMorgan downgraded Avantor from Overweight to Neutral, highlighting a 4.7% decline in organic revenue, which was below expectations. BofA Securities also lowered its price target for Avantor to $14.00 from $16.50, although it maintained a Buy rating, expressing concerns over pricing challenges. Additionally, Avantor launched a new suite of bioprocessing solutions for sterile sampling, aiming to enhance operational efficiency. The new product line includes various sampling systems designed for different applications and safety requirements. These developments reflect Avantor’s ongoing efforts to address market challenges and expand its product offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.